RxDoctor Payments Data

Robert Chavez, MD

Internal Medicine · New York, NYNPI 1326113069

Payments from drug & device makers

$144,618in general payments, 2019–2025

Across 394 payments — averaging $367.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$133K
  • Viiv Healthcare Company$6K
  • Theratechnologies Inc.$3K
  • Idorsia Pharmaceuticals US Inc$1K
  • EMD Serono, Inc.$466
  • Antares Pharma, Inc.$175
  • plus $335 from 4 others

What the payments were for

  • Consulting fees$9,3706%
  • Speaking & faculty fees$115,39080%
  • Travel & lodging$11,7978%
  • Food & beverage$8,0496%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,618 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$108,449
Medicare patients
234
Services billed
11,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin122$2,551,987
GenvoyaElviteg/Cob/Emtri/Tenof Alafen115$497,887
BiktarvyBictegrav/Emtricit/Tenofov Ala92$439,946
TriumeqAbacavir/Dolutegravir/Lamivudi89$361,343
DovatoDolutegravir Sodium/Lamivudine114$340,969
DescovyEmtricitabine/Tenofov Alafenam103$244,680
TivicayDolutegravir Sodium93$230,648
PrezcobixDarunavir/Cobicistat77$199,880
IsentressRaltegravir Potassium89$185,632
JulucaDolutegravir/Rilpivirine38$143,946
CabenuvaCabotegravir/Rilpivirine15$100,045
RukobiaFostemsavir Tromethamine11$96,345
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$70,841
StribildElviteg/Cob/Emtri/Tenofo Disop14$54,771
EdurantRilpivirine Hcl35$50,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Serostim$466$2,551,987122 claims
Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Juluca, Cabenuva$5,824$1,273,295360 claims
GileadGenvoya, Biktarvy, Descovy, Stribild$133,332$1,237,284324 claims
MerckIsentress, Pifeltro, Januvia$111$218,874125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →